-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Enticave (ETV) is a nucleoside antiviral drug used in the treatment of chronic hepatitis B.
the drug was first developed by Shishi Shiguibao, first approved in China in 2005, has become a first-line treatment of hepatitis B drugs.
public data show that in 2019, the domestic public medical institutions terminal Endikave sales of more than 7 billion yuan, but mainly tablets and capsules, the market share with a positive day, 48.93 percent, the original research ShiGuibao accounted for 26.44 percent.
The Insight database shows that there are currently six dosage forms in the country, including tablets, dispersion tablets, capsules, oral solutions, particles and Malay acid entecawe tablets.
, the first three of them have been included in the 4 plus 7 episodes, the 33 in this Yangzijiang before the approval, there has not been a domestic generic drug approval.
from: Insight database () for Entekave oral solution, the original research hundred-time Meishi Guibao pharmaceutical is still in clinical applications, there are few domestic enterprises to apply.
addition to the yangzijiang pharmaceutical industry approved this time, Only Anhui New Century Pharmaceuticals submitted a new registration classification listing application on September 17 this year.
addition, Stadt Pharmaceuticals was approved for clinical practice in December 2019.
from: Insight Database ()
